Study Finds Arthritis Drug Enbrel Overpatented, Overpriced in US 04/12/2018 by Intellectual Property Watch Leave a Comment Initiative for Medicines, Access & Knowledge (I-MAK) released a new study yesterday showing that the rheumatoid arthritis drug Enbrel has been overpatented by drugmaker Amgen, which has filed a total of 57 patents on the drug in the United States. Together, these patents were said to delay market competition by 39 years, rather than the standard 20 years for one patent. The study found that this market exclusivity for Enbrel resulted in US$ 8 billion dollars in sales in 2017 alone.
WHO Director Tedros Gives Thoughts On Access To Medicines, Gene Editing, Ebola 03/12/2018 by Catherine Saez, Intellectual Property Watch Leave a Comment World Health Organization Director General Tedros Adhanom Ghebreyesus (Dr Tedros) met with United Nations journalists today, in what he said would become a regular end-of-the-year meeting with the press. He gave an update on the ongoing Ebola outbreak and his views on the recent human gene editing by a Chinese researcher, and on the use of gene drive organisms to fight malaria. He also provided his views on access to affordable and safe medicines.
China Pulling The Cart To Propel Global IP Filings To New Heights, Trademarks Skyrocketing – WIPO 03/12/2018 by Catherine Saez, Intellectual Property Watch Leave a Comment Global intellectual property filing numbers kept rising unabated in 2017, as China continued to pull the numbers upwards. The World Intellectual Property Indicators 2018, published today, also showed what the head of the World Intellectual Property Organization qualified as extraordinary growth in trademark applications. And he remarked on the increasing importance of intellectual property in the contemporary economy.
Conferences On Medicines Patent Information, Patent Office Cooperation, At WIPO This Week 03/12/2018 by Catherine Saez, Intellectual Property Watch Leave a Comment The World Intellectual Property Organization patent law committee meeting this week will convene two half-day conferences, one on cooperation between patent offices, and the other on publicly accessible databases on patent information on medicines and vaccines. Other topics for discussion will be patents and health, confidentiality of communications between patent applicants and their advisors, quality of patents, and the research exception.
CBD Biennial Meeting Closes With Resolutions On Digital Sequence Data, Conflicts Of Interest, Global Benefit-Sharing 30/11/2018 by Catherine Saez, Intellectual Property Watch 1 Comment The biennial meeting of the Convention on Biological Diversity and its protocol on access and benefit-sharing closed yesterday with a list of adopted decisions. Among them was a decision to commission several studies on the impact of digital sequence data on the CBD for a recommendation at the next meeting in 2020. Delegates also agreed on a study to examine cases of genetic resources, and traditional knowledge associated with genetic resources, not yet covered by the protocol. Also adopted is the first decision on the management and prevention of conflicts of interest in expert groups.
Economically Sound And Fair Global Genetics Benefit-Sharing System Possible, Panellists Say 29/11/2018 by Catherine Saez, Intellectual Property Watch Leave a Comment SHARM EL-SHEIKH, Egypt — UN Convention on Biological Diversity members were trying this week to address questions that were left open when its protocol on access and benefit-sharing was adopted eight years ago. One of them is how to deal with genetic resources which are not yet covered by the protocol. A side event to the biennial conference of CBD members this week presented a solution, which they say could provide a more efficient, cost-effective and fairer system of access and benefit-sharing, based on inventions protected by intellectual property rights.
UN Biodiversity Convention Agrees On Precautionary Approach To Synthetic Biology 29/11/2018 by Catherine Saez, Intellectual Property Watch Leave a Comment SHARM El-SHEIKH, Egypt — While the world has been taken by surprise after a Chinese researcher declared he had genetically modified twin babies, and critics are rising from all parts, the Convention on Biological Diversity adopted a decision on synthetic biology today at the close of its biennial meeting. The decision which calls for a precautionary approach was hailed by civil society groups which were calling for a moratorium preventing gene drive organisms to be released in the wild.
Shared Indigenous Knowledge And Benefit-Sharing Needs Particular Attention, Panel Tells CBD 29/11/2018 by Catherine Saez, Intellectual Property Watch Leave a Comment SHARM El-SHEIKH, Egypt — Traditional knowledge associated with genetic resources held by indigenous and local communities is often not confined to one group or one specific geographical location. Displacement whether cultural or forced, political redesigning of borders, and exchanges with other communities have all contributed to the dispersion of that knowledge. This shared knowledge poses an issue in the context of benefit-sharing of commercial benefits on inventions derived from this knowledge. A side event on the side of the biennial meeting of the UN Convention on Biological Diversity looked at how to address shared traditional knowledge.
Gene Editing Divides UN Biodiversity Convention Members On Synthetic Biology Evaluation 28/11/2018 by Catherine Saez, Intellectual Property Watch Leave a Comment SHARM EL-SHEIKH, Egypt — After informal closed consultations, a draft decision was issued yesterday on how the UN Convention on Biological Diversity should address potential impacts of synthetic biology, during the biennial conference of the parties taking place this week. The issue of the release of gene drive organisms into the environment was a contentious issue as civil society had been lobbying for a moratorium preventing the release into the wild of those organisms able to wipe out entire species. This morning consensus was still eluding delegates, particularly over the singling out of gene editing in the decision.
New Database Documents The Power Of TRIPS Flexibilities 28/11/2018 by Intellectual Property Watch Leave a Comment Ellen ‘t Hoen writes: Medicines Law & Policy has published an on-line database of instances of the use of TRIPS flexibilities in public health contexts, titled the TRIPS Flexibilities Database. The publication of the TRIPS Flexibilities Database merits sharing a bit of its history because it has been a work in progress for some time. The database includes cases of actual use of TRIPS flexibilities and instances in which countries planned or threatened to use them. The collection of such cases started ten years ago as part of a research project to document and examine the uptake of the flexibilities contained in the TRIPS Agreement in medicines procurement.